A Randomized, sequential, ascending-dose, double blind, placebo-controlled study to investigate pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban administered in healthy Japanese male subjects.
Phase of Trial: Phase I
Latest Information Update: 07 May 2014
Price : $35 *
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
- Focus Therapeutic Use
- 07 May 2014 New trial record
- 14 Apr 2014 Results published in the International Journal of Clinical Pharmacology and Therapeutics.